Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of MOnaliZumab in Combination With durvAlumab (MEDI4736) for tReatmenT of Small Cell Lung Cancer (MOZART)

NCT05903092 is registered in ClinicalTrials.gov with Hirva Mamdani as lead sponsor.

NCT NCT05903092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05903092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of MOnaliZumab in Combination With durvAlumab (MEDI4736) for tReatmenT of Small Cell Lung Cancer (MOZART)
Lead sponsor
Hirva Mamdani
Phase
Phase 2
Overall status
Recruiting
Start date
September 26, 2023
Completion date
October 31, 2030
Enrollment
84 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage small cell lung cancer, limited stage small-cell lung cancer, sclc, small cell lung cancer